Key Products: Pemvidutide, balanced 1:1 dual GLP-1/glucagon receptor agonist, designed to drive both appetite suppression (GLP-1) and direct hepatic fat oxidation (glucagon)
10.1016/j.lfs.2019.117152 8
Electrical excitability and ion channels
Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al
Kamlesh Khunti has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme
Patients on semaglutide had a decreased risk of heart failure, coronary revascularization, kidney failure and even, all-cause mortality